Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT03-65 in Advanced Solid Tumors
NCT06809114Phase 1Recruiting
- Sponsor
- Axcynsis Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AT03-65 in solid tumor, sponsored by Axcynsis Therapeutics. Primary endpoints: Maximum Tolerated Dose at 21 days and Dose-Limiting Toxicity at 21 days. Started Jan 2026; status: recruiting.
02
Drugs
AT03-65
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06809114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809114.